Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05019521 · ClinicalTrials.gov registry record · Phase 2
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 365
- Enrollment target
NCT05019521 is a Phase 2 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 365 participants.
The verdict
NCT05019521, a Phase 2 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 365 participants
- Enrollment target
Study Summary
This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.
Interventions
- DRUG Placebo
- DRUG Danicopan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2025-01-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05019521
The ClinicalTrials.gov registry entry for NCT05019521 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05019521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05019521 about?
NCT05019521 is a clinical study titled "A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration". This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This ...
What is the current status of trial NCT05019521?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 365 participants. The study started on 2021-08-23. Estimated completion is 2025-01-21.
What interventions are being tested in trial NCT05019521?
The interventions under investigation include: Placebo (DRUG), Danicopan (DRUG).
Who is sponsoring clinical trial NCT05019521?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.